AzTrials
AzTrials

Advanced Non Small Cell Lung CancerPhase 2NCT04239443

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

A Phase 2 study testing PD-1 inhibitor and Apatinib in people with Advanced Non Small Cell Lung Cancer and Uterine Cancer, run by Hunan Cancer Hospital at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

In this one-arm study, histologically or cytologically confirmed advanced NSCLC, uterine malignancies, and soft tissue sarcoma will be enrolled to investigate the efficacy and safety of PD-1 monoclonal antibody SHR-1210 and apatinib, at the same time, peripheral circulating blood tumor cells (CTC) detection and… Read more about this study

Who is it for?
Ages 18 to 70 years
What is being tested?
PD-1 inhibitor and Apatinib
Could I receive a placebo?
No, everyone receives an active treatment
How many people
120 participants
Where
1 siteChina
Study dates
30 Jan 2019to 31 Mar 2022
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18-70 years, both men and women (Uterine cancer limited to women);
  • NSCLC: Pathologically confirmed advanced (IIIB, stage IV) NSCLC with at least 1 measurable lesion that meets the RECIST v1.1 standard without local treatment, of which stage IIIb patients are incapable, unsuitable for surgery or radical radiotherapy, NSCLC patients have failed at least the first-line standard treatment or refused to receive standard treatment, or chemotherapy intolerance, Among them, patients with sensitive gene mutations must fail after TKI treatment (patients who have failed first-line or second-line treatment may participate in this study), Patients with EGFR and ALK mutations must undergo EGFR and ALK inhibitor treatment failure and EGFR T790M mutation negative, for EGFR T790M-positive patients, third-generation EGFR TKI treatment fails.
  • Soft tissue sarcoma: Patients with distant metastasis or locally advanced disease who have previously failed chemotherapy or sensitive recurrence or metastasis to soft tissue sarcoma. Subjects who have judged by the investigator to be unsuitable for surgical treatment (including amputation) of soft tissue sarcomas (diagnosed pathologically or cytologically, but excluding gastrointestinal stromal tumors, chondrocyte-bone tumors, embryonic/acinar rhabdomyosarcoma, Juventus Sarcoma, extensive distant metastatic soft tissue tumors such as keloid cutaneous fibrosarcoma and inflammatory myofibroblastic sarcoma, malignant peripheral nerve sheath tumor, keloid cutaneous fibrosarcoma, inflammatory myofibroblastic sarcoma, malignant interstitial Dermatoma) (priority consideration: synovial sarcoma, undifferentiated multiline sarcoma, dedifferentiated liposarcoma), and measurable lesions that meet the RECIST 1.1 standard.
  • Uterine cancer: Pathologically confirmed uterine cancer, including cervical cancer (squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma), endometrial cancer, and uterine sarcoma, at least one measurable lesion that meets RECIST 1.1 criteria, recurrence/Persons with persistent cervical cancer, endometrial cancer, and uterine sarcoma cannot be cured by surgery and/or radiotherapy, have received at least a first-line treatment for advanced (stage IVB), recurrent/persistent cervical cancer, endometrial cancer, uterine sarcoma Systemic chemotherapy patients (qualified to participate in this study after the progress of first-line chemotherapy).
  • All acute toxicity caused by previous antitumor treatments were alleviated to level 0-1 (according to NCI CTCAE version 4.03) or to the level specified by the enrollment/ exclusion criteria 1 day before the first dose except for subjects whose toxicity does not pose a safety risk);
  • Able to provide tumor samples (at least 20 unstained tumor samples or fresh tissue specimens embedded in formalin-fixed paraffin within six months, 4ml of peripheral blood samples before treatment and each effect evaluation);
Show all 19Show fewer
  • ECOG score: 0-1, patients with soft tissue sarcoma amputation can be relaxed to 2 points;
  • Expected survival ≥ 12 weeks;
  • The function of important organs meets the following requirements (excluding the use of any blood components and cell growth factors during screening);
  • Absolute neutrophil count ≥1.5 × 109 / L;
  • platelets ≥100 × 109/L;
  • Hemoglobin ≥9g/dL;
  • serum albumin ≥3g/dL;
  • total bilirubin ≤ 1.5ULN;
  • ALT and AST ≤1.5ULN;
  • AKP ≤ 2.5ULN;
  • Serum creatinine ≤ 1.5ULN or creatinine clearance ≥ 60mL/min;
  • Non-surgical sterilization female patients;
  • Participants volunteered to participate in the study, signed informed consent, good compliance, and cooperated with the follow-up.

Who cannot join

  • Participants who had any active autoimmune disease or a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis , Hyperthyroidism, decreased thyroid function; subjects with vitiligo or childhood asthma has completely resolved, adults can be included without any intervention; subjects with bronchodilators for medical intervention can not be included in asthma;
  • Participants who were treated with immunosuppressive agents, or systemic or absorbable local hormones for immunosuppressive purposes (dose>10mg/day, prednisone or other curative hormones), and continued to use it within 2 weeks before enrollment;
  • Excessive allergic reactions to other monoclonal antibodies;
  • Participants who had clinical symptoms of central nervous system metastases (such as brain edema, require hormonal intervention, or progress of brain metastases). Participants who had previously received brain or meningeal metastasis treatment, such as clinical stability (MRI) that has been maintained for at least 1 month, and have stopped systemic hormonal therapy (dose> 10 mg / day prednisone or other therapeutic hormone) can be included;
  • Imaging (CT or MRI) showed that the tumor invades or demarcates large blood vessels.
  • Imaging (CT or MRI) showed obvious hollow or necrotic tumors in the lungs; those with marginal adenocarcinoma with cavities can be considered after discussion with the clinician.
Show all 26Show fewer
  • Participants who had high blood pressure and cannot be well controlled with antihypertensive medication (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90 mmHg).
  • Participants who had poorly controlled clinical symptoms or diseases of the heart, such as: (1) heart failure above NYHA 2 (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) clinically significant supraventricular Sexual arrhythmias require treatment or intervention.
  • Participants who had abnormal blood coagulation (PT> 16s, APTT> 43s, TT> 21s, Fbg <2g / L), bleeding tendency or receiving thrombolytic or anticoagulation；
  • Urine routine indicates urinary protein ≥ ++, or confirms that 24-hour urine protein is ≥1.0 g；
  • Participants who previously received radiotherapy, chemotherapy, hormone therapy, surgery or molecular targeted therapy. After treatment is completed (last dose), subjects less than 4 weeks before study medication (or 5 drug half-life, whichever is longer) Patients who did not recover from adverse events (excluding hair loss) from previous treatment to ≤CTCAE 1 degree；
  • Clinically ascites or pleural effusion requiring therapeutic puncture or drainage；
  • Participants who had obvious cough blood in the first 2 months of randomization, or a day with hemoptysis of half teaspoon (2.5ml) or more；
  • Participants who had clinically significant bleeding symptoms or have a clear bleeding tendency within the first 3 months of randomization, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult blood at baseline and above, or have vasculitis；
  • Participants who had arterial/venous thrombotic events such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism occurred within the first 6 months；
  • Participants who had known hereditary or acquired bleeding and thrombotic tendency (eg hemophilia, coagulopathy, thrombocytopenia, hypersplenism, etc.)；
  • Participants who had an active infection or an unexplained fever during the screening period before the first dose> 38.5 degrees;
  • Patients with past and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe impairment of lung function, etc;
  • Participants who had congenital or acquired immune deficiency (such as HIV-infected persons), or positive for syphilis spiral antibodies, or active hepatitis (HBV reference: HBsAg positive, and HBV DNA detection exceeds the upper limit of normal values; (And the HCV virus titer detection value exceeds the upper limit of normal value);
  • Participants who have used other drugs in clinical trials within 4 weeks before the first use;
  • Participants has previous or concurrent other malignancies (except cured skin basal cell carcinoma and cervical carcinoma in situ);
  • Participants may receive other systemic anti-tumor treatments during the study;
  • Participants with bone metastases who had received palliative radiation therapy within 4 weeks before participating in the study;
  • Participants who have previously received other PD-1 antibody treatments or other immunotherapy against PD-1/PD-L1 or VEGFR single-target/multi-target inhibitors, such as Sunitinib, Sorafeni, Bevacizumab, Anlotinib, Famitinib, Apatinib, and Reginafinib (in advanced NSCLC, there is no need to exclude previous VEGFR single / multitarget inhibitor Patients treated, but need to be discontinued for more than 4 weeks);
  • Live vaccine may be given less than 4 weeks before study medication or possibly during the study;
  • According to the researcher's judgment, Participants has other factors that may lead to the termination of the study. Serious diseases (including mental illness) require combined treatment. There are serious laboratory abnormalities, accompanied by family or social factors. To the safety of the subject, or the collection of information and samples;

Trial locations and contacts

1 site in 1 country.

Nong Yang contact

+8613055193557

yangnong0217@163.com

China1 site, 1 recruiting

  • Hunan cancer Hospital

    Changsha, Hunan, 410013

    Nong Yang, +8613055193557, yangnong0217@163.com

    Recruiting

Other trials in China

About this study

Official title: Peripheral Circulating Blood Tumor Cells (CTC) Detection and CTC-based PD-L1 Antibody Immunofluorescence Detection to PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Second-line and Back-line Treatment of Advanced NSCLC, Soft Tissue Sarcoma, Uterine Cancer Clinical Research

In this one-arm study, histologically or cytologically confirmed advanced NSCLC, uterine malignancies, and soft tissue sarcoma will be enrolled to investigate the efficacy and safety of PD-1 monoclonal antibody SHR-1210 and apatinib, at the same time, peripheral circulating blood tumor cells (CTC) detection and CTC-based PD-L1 antibody immunofluorescence detection will be performed.

Read the detailed description

Primary outcome:

  1. Analysis of baseline levels of CTC and CTC PD-L1 and prognosis efficacy of patients: Objective remission rate (ORR), progression free survival (PFS), overall survival (OS);
  2. Dynamic monitoring of CTC and CTC PD-L1 at baseline before treatment, after two cycles of treatment, and as the disease progresses.
  3. Consistency analysis of PD-L1 and CTC PD-L1 expression in tissue specimens.

Secondary outcome:

Duration of response(DOR), Disease control rate(DCR), Safety of the combination therapy.

Being tested
PD-1 inhibitor, Apatinib
Keywords
immunotherapy, PD-1 checkpoint inhibitor, circulating blood tumor cells (CTC)
Medical subject headings
Uterine Neoplasms, Sarcoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PD-1 inhibitorDrug

    Also called Camrelizumab

    Intravenous administration of SHR1210 (200mg/2weeks or 200mg/3weeks)

  • ApatinibDrug

    NSCLC and Uterine cancer will be given oral of Apatinib (250mg/d), soft tissue sarcoma will be given oral of Apatinib (500mg/d).

Study groups in NCT04239443
Study groupRoleWhat they receive
SHR1210 and ApatinibExperimentalNSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d). The duration of treatment will till the disease progression, death, or unacceptable toxicity show up.
Receives: Drug: PD-1 inhibitor; Drug: Apatinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective remission rate (ORR)

    Evaluated by researchers based on the RECIST 1.1 standard

    Measured: 2 years

  2. Progression free survival (PFS)

    Evaluated by researchers based on the RECIST 1.1 standard

    Measured: 2 years

  3. Overall survival (OS)

    Evaluated by researchers based on the RECIST 1.1 standard

    Measured: 2 years

  4. The number of Circulating Tumor Cell (CTC)

    Measured: 2 years

  5. Analysis of PD-L1 expression on Circulating Tumor Cell (CTC) and tumor tissue

    Measured: 2 years

Secondary outcomes (2)

  1. Duration of response(DOR)

    Evaluated by researchers based on the RECIST 1.1 standard

    Measured: 2 years

  2. Disease control rate(DCR)

    Evaluated by researchers based on the RECIST 1.1 standard

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Jan 2020
  2. Study start30 Jan 2019
  3. Primary completion31 Mar 2022 (estimated)
  4. Study completion31 Mar 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Patients fulfilling Eligibility Criteria will be included in our study. NSCLC participants will be given intravenous administration of SHR-1210 (200mg/2w) and oral of Apatinib (250mg/d) , soft tissue sarcoma will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (500mg/d), and uterine cancer will be given intravenous administration of SHR-1210 (200mg/3w) and oral of Apatinib (250mg/d). Treatments will be administrated until disease progression, death, or unacceptable toxicity.
Masking
None (open label)
Enrolment
120 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04239443
Sponsor's protocol ID
HNCHIIT001
Status last verified
Jan 2020
First submitted
14 Jan 2020
Last updated
27 Jan 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: \[contact information for Sponsor Investigator or designee\]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing PD-1 inhibitor and Apatinib in people with Advanced Non Small Cell Lung Cancer and Uterine Cancer, run by Hunan Cancer Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Nong Yang (+8613055193557, yangnong0217@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective remission rate (ORR) (time frame: 2 years). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04239443.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jan 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in